Navidea Biopharmaceuticals has secured $30 million in a stock offering. The company will use the proceeds to finance expansion efforts, including bringing its Lymphoseek radiopharmaceutical to markets abroad.
Published in Brief:
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||